Obermatt

Cryoport

NAQ:CYRX · US2290503075
Life Sciences Tools & ServicesMedium

360

83
Profit price38
Owner Earnings Yield99
Dividend Yield1
Price/Sales47
EV / Gross Profit61
Price/Book64
Return on Capital44
Cash Return on Capital97
Return on Equity48
EBIT Margin34
Gross Profitability24
Cash Conversion6
Accruals91
Owner Earnings Margin98
Sales growth77
Profit Growth25
Long-Term EPS Growth56
Owner Earnings Growth44
Reinvestment46
Price momentum89
Debt load50
Refinancing45
Debt Payback100
Liquidity22
Analyst ratings85
Opinion Changes50
Price Target Upside24
Market mood51
Value Creation10/20creating some value
  • Creates more value than its capital costs
  • Owner earnings growing
  • Owner earnings per share growing
  • Reinvests at strong returns
  • Solid earnings base

What this means

Cryoport clears its cost of capital, but the record is mixed across the five tests. Real value creation, just not yet consistent.

Profile

CountryUSA
IndustryLife Sciences Tools & Services
SizeMedium
TypePublic Company
ExchangeNASDAQCM
Employees271
ISINUS2290503075
Last UpdateApr 2, 2026
Themes
Freight ServiceHealth DiagnosticsPackaging ServicesClinical TrialsLogisticsShipping

Description

Cryoport, Inc. (Cryoport) provides integrated, temperature-controlled supply chain solutions for the life sciences sector, with a primary focus on supporting the cell and gene therapy (CGT) market. The company's solutions are purpose-built to suppor…

Analysis

Middle-of-the-road

Cryoport, Inc. sits in the middle of our grid: average quality, average price, no obvious signal in either direction.

On valuation, the picture is attractive. The owner-earnings multiple stands at 8.7×; owner earnings: the cash an owner could take out each year. The implied growth embedded in that price is around -5% a year, against analyst forecasts of 10%. The price, in other words, assumes less than the experts do.

Growth is moderate; the safety picture is adequate. The company scores 10/20 on our value-creation score: creating some value.

Flags to be aware of: Reported profits have run ahead of actual cash for several periods. As always: this describes the company's numbers; it is not a recommendation.

360° rank · history

1007550250
68
2023202420252026

All-time high

68

Jun 2026

All-time low

15

Jan 2024

Average rank

43

across all years

Detailed & Historical Ranks

Deep dive into 15 detailed ranks and 3 years of history.

Current202520242023
Price/Sales
47
81
68
35
Price/Earnings
92
82
82
2
Price/Book
64
91
79
63
Dividend Yield
1
1
1
1
Value (overall)
65
77
70
43

Cells are coloured by rank band (red weak → green strong). Sentiment & 360° history begins 2023.

Similar Stocks

The companies this stock is ranked against.

Compare Cryoport with its peers
Azenta
NSQ:AZTA
35
CountryUSA
IndustryLife Sciences Tools & Services
SizeMedium
Full Stock Analysis →
Pacific Biosciences of California
NSQ:PACB
16
CountryUSA
IndustryLife Sciences Tools & Services
SizeSmall
Full Stock Analysis →
IQVIA
NYQ:IQV
49
CountryUSA
IndustryLife Sciences Tools & Services
SizeX-Large
Full Stock Analysis →
BioLife Slutn
NAQ:BLFS
50
CountryUSA
IndustryLife Sciences Tools & Services
SizeSmall
Full Stock Analysis →
Bionano Genomics
NAQ:BNGO
17
CountryUSA
IndustryLife Sciences Tools & Services
SizeSmall
Full Stock Analysis →
10x Genomics
NSQ:TXG
38
CountryUSA
IndustryLife Sciences Tools & Services
SizeMedium
Full Stock Analysis →

Make Sense of the Ranks

Every rank runs 1–100 against true peers. Higher is always better.

360° View
1 · Watch OutGood· 100
Value
1 · ExpensiveGood Value· 100
Quality
1 · Weak FundamentalsHigh Quality· 100
Growth
1 · Tough TimesHigh Growth· 100
Safety
1 · High LeverageWell-Financed· 100
Sentiment
1 · SkepticismPositive· 100
Learn More →